SMR4 Antibody

Overview of SMARCA4 and Associated Antibodies

SMARCA4 (BRG1) is a critical component of the SWI/SNF chromatin remodeling complex, involved in transcriptional regulation and DNA repair. Dysregulation of SMARCA4 is linked to oncogenesis, with mutations occurring in >20% of cancers . Antibodies targeting SMARCA4 are widely used in cancer research and diagnostics.

Role in Cancer Biology

SMARCA4 loss or mutation is associated with:

• Increased tumor aggressiveness .

• Enhanced likelihood of response to immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 therapies) .

• Mosaic staining patterns in tumors, suggesting clonal heterogeneity .

Technical Validation

• MSVA-397R: Validated against a second independent antibody to confirm specificity in SMARCA4-deficient tumors .

• BSM-61308R: Detects SMARCA4 in nuclear compartments across human, mouse, and rat tissues .

Therapeutic Implications

While no SMARCA4-targeted therapies are approved, preclinical studies highlight:

• Synthetic lethality in SMARCA4-deficient cancers when combined with PARP inhibitors .

• Potential as a biomarker for immunotherapy response .

Challenges and Future Directions

• Validation Complexity: Antibodies like MSVA-397R require cross-validation due to variable staining patterns in tumors .

• Functional Studies: The biological impact of SMARCA4 expression levels (reduced/normal/increased) remains poorly understood .

• Therapeutic Development: Emerging technologies, such as AI-driven antibody design , may accelerate SMARCA4-targeted drug discovery.